title: Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia.
authors.affiliation: Department of Medicine, Queen Mary Hospital, Pokfulam Road, Hong Kong, China.
authors.forename: Thomas S Y
authors.initials: TS
authors.lastname: Chan
authors.affiliation: Department of Pathology, Queen Mary Hospital, Pokfulam Road, Hong Kong, China.
authors.forename: Rex
authors.initials: R
authors.lastname: Au-Yeung
authors.affiliation: Department of Medicine, Queen Mary Hospital, Pokfulam Road, Hong Kong, China.
authors.forename: Chor-Sang
authors.initials: CS
authors.lastname: Chim
authors.affiliation: Department of Microbiology, Queen Mary Hospital, Pokfulam Road, Hong Kong, China.
authors.forename: Sally C Y
authors.initials: SC
authors.lastname: Wong
authors.affiliation: Department of Medicine, Queen Mary Hospital, Pokfulam Road, Hong Kong, China. ylkwong@hkucc.hku.hk.
authors.forename: Yok-Lam
authors.initials: YL
authors.lastname: Kwong
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000077329:Agammaglobulinaemia Tyrosine Kinase; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005334:Fever / Q000209:etiology / Q000517:prevention & control; D060585:Fusariosis / Q000150:complications* / Q000276:immunology / Q000382:microbiology / Q000503:physiopathology; D005670:Fusarium / Q000187:drug effects / Q000276:immunology / Q000302:isolation & purification; D006801:Humans; D016867:Immunocompromised Host; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D000072281:Lymphadenopathy / Q000209:etiology / Q000517:prevention & control; D060046:Maintenance Chemotherapy; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D009894:Opportunistic Infections / Q000150:complications* / Q000276:immunology / Q000382:microbiology / Q000503:physiopathology; D010880:Piperidines; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D011505:Protein-Tyrosine Kinases; D000077329:Agammaglobulinaemia Tyrosine Kinase; D000225:Adenine